private financing

Under the terms of the agreement, OpGen would sell $10 million in stock and warrants to a US-based healthcare-focused institutional investor.

The firm said the funding will support the launch of its miniaturized ELISA platform, which reduces the time and sample volume required for such assays.

Illumina Ventures led the round for the Santa Clara, California-based firm, which is developing applications for its optical detection technology.

The company said the funds would be used in part to expand its presence in the cell-analysis market in areas such as infectious disease.

The company has developed a platform, called e[datascientist], that uses artificial intelligence to analyze genomic and microbiomic data at scale.

Investors in the round included International Holdings Company (IHC), based in Abu Dhabi, United Arab Emirates, and RPMI Railpen, a UK pension fund.

Investors included Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging technology.